 Piperidines
"Piperidines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A family of hexahydropyridines.
| Descriptor ID |
D010880
|
| MeSH Number(s) |
D03.383.621
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Piperidines".
Below are MeSH descriptors whose meaning is more specific than "Piperidines".
This graph shows the total number of publications written about "Piperidines" by people in UAMS Profiles by year, and whether "Piperidines" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2025 | 1 | 1 | 2 | | 2024 | 3 | 1 | 4 | | 2021 | 0 | 2 | 2 | | 2020 | 1 | 5 | 6 | | 2019 | 2 | 2 | 4 | | 2018 | 0 | 1 | 1 | | 2017 | 6 | 1 | 7 | | 2016 | 1 | 2 | 3 | | 2015 | 3 | 2 | 5 | | 2014 | 4 | 3 | 7 | | 2013 | 3 | 1 | 4 | | 2012 | 3 | 0 | 3 | | 2011 | 3 | 1 | 4 | | 2010 | 3 | 1 | 4 | | 2009 | 2 | 3 | 5 | | 2008 | 0 | 2 | 2 | | 2007 | 1 | 3 | 4 | | 2006 | 1 | 3 | 4 | | 2005 | 1 | 1 | 2 | | 2004 | 3 | 2 | 5 | | 2003 | 0 | 1 | 1 | | 2001 | 0 | 1 | 1 | | 1997 | 0 | 1 | 1 | | 1995 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Piperidines" by people in Profiles over the past ten years.
-
James JC, Thrush JR, Yusufali TM, Shaw HE, Avram M, Moran JH, Fantegrossi WE. Synthetic cannabinoid receptor agonists exacerbate fentanyl-elicited respiratory depression and confer resistance to naloxone rescue in mice. Drug Alcohol Depend. 2025 Jul 01; 272:112672.
-
Surico PL, Naderi A, Singh RB, Kahale F, Farsi Y, Lee S, Musayeva A, Chen Y, Dana R. Antagonizing NK-1R modulates pain perception following corneal injury. Exp Eye Res. 2025 Feb; 251:110230.
-
Syal G, Mishkin DS, Banty A, Lee S, Fontelera N, Hampton M, Ziring D, Fleshner PR, Melmed GY. Effectiveness of Oral Tofacitinib in Chronic Pouchitis: A Prospective, Open-Label Pilot Study. Inflamm Bowel Dis. 2024 10 03; 30(10):1907-1910.
-
Arnaoutakis K, Wan Y, Elliott J, Young M, Yin Y, Leventakos K, Lin HM, Dimou A. Real-World Treatment Patterns and Outcomes Across Three Lines of Therapy in Patients with ALK+ NSCLC. Adv Ther. 2024 Aug; 41(8):3217-3231.
-
Hersey M, Mereu M, Jones CS, Bartole MK, Chen AY, Cao J, Hiranita T, Chun LE, Lopez JP, Katz JL, Newman AH, Tanda G. Dual DAT and sigma receptor inhibitors attenuate cocaine effects on nucleus accumbens dopamine dynamics in rats. Eur J Neurosci. 2024 May; 59(10):2436-2449.
-
Yu N, Raslan OA, Lee HS, Theeler BJ, Raafat TA, Fragoso R, Shahlaie K, Aboud O. Promising response to vemurafenib and cobimetinib treatment for BRAF V600E mutated craniopharyngioma: a case report and literature review. CNS Oncol. 2024 01 01; 13(1):CNS106.
-
Harding EK, Dedek A, Bonin RP, Salter MW, Snutch TP, Hildebrand ME. The T-type calcium channel antagonist, Z944, reduces spinal excitability and pain hypersensitivity. Br J Pharmacol. 2021 09; 178(17):3517-3532.
-
Al-Zubaidi U, Adhikari D, Cinar O, Zhang QH, Yuen WS, Murphy MP, Rombauts L, Robker RL, Carroll J. Mitochondria-targeted therapeutics, MitoQ and BGP-15, reverse aging-associated meiotic spindle defects in mouse and human oocytes. Hum Reprod. 2021 02 18; 36(3):771-784.
-
Ord??ez PE, Mery DE, Sharma KK, Nemu S, Reynolds WF, Enriquez RG, Burns DC, Malag?n O, Jones DE, Guzman ML, Compadre CM. Synthesis, Crystallography, and Anti-Leukemic Activity of the Amino Adducts of Dehydroleucodine. Molecules. 2020 Oct 20; 25(20).
-
Fenster M, Alayo QA, Khatiwada A, Wang W, Dimopoulos C, Gutierrez A, Ciorba MA, Christophi GP, Hirten RP, Ha C, Beniwal-Patel P, Cohen BL, Syal G, Yarur A, Patel A, Colombel JF, Pekow J, Ungaro RC, Rubin DT, Deepak P. Real-World Effectiveness and Safety of Tofacitinib in Crohn's Disease and IBD-U: A Multicenter Study From the TROPIC Consortium. Clin Gastroenterol Hepatol. 2021 10; 19(10):2207-2209.e3.
-
Deepak P, Alayo QA, Khatiwada A, Lin B, Fenster M, Dimopoulos C, Bader G, Weisshof R, Jacobs M, Gutierrez A, Ciorba MA, Christophi GP, Patel A, Hirten RP, Colombel JF, Rubin DT, Ha C, Beniwal-Patel P, Ungaro RC, Syal G, Pekow J, Cohen BL, Yarur A. Safety of Tofacitinib in a Real-World Cohort of Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol. 2021 08; 19(8):1592-1601.e3.
-
Moore Ii JP, Dachavaram SS, Bommagani S, Penthala NR, Venkatraman P, Foster EJ, Crooks PA, A Hestekin J. Oxone?-Mediated TEMPO-Oxidized Cellulose Nanomaterials form I and form II. Molecules. 2020 Apr 17; 25(8).
-
Chari A, Cornell RF, Gasparetto C, Karanes C, Matous JV, Niesvizky R, Lunning M, Usmani SZ, Anderson LD, Chhabra S, Girnius S, Shustik C, Stuart R, Lee Y, Salman Z, Liu E, Valent J. Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma. Hematol Oncol. 2020 Aug; 38(3):353-362.
-
Zhou X, Steinhardt MJ, D?ll J, Krummenast F, Danhof S, Meckel K, Nickel K, Grathwohl D, Leicht HB, Rosenwald A, Einsele H, Rasche L, Kort?m M. Obinutuzumab and venetoclax induced complete remission in a patient with ibrutinib-resistant non-nodal leukemic mantle cell lymphoma. Eur J Haematol. 2020 Apr; 104(4):352-355.
-
Mirza MR, ?vall Lundqvist E, Birrer MJ, dePont Christensen R, Nyvang GB, Malander S, Anttila M, Werner TL, Lund B, Lindahl G, Hietanen S, Peen U, Dimoula M, Roed H, ?r Knudsen A, Staff S, Krog Vistisen A, Bj?rge L, M?enp?? JU. Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial. Lancet Oncol. 2019 10; 20(10):1409-1419.
-
Bukhari A, El Chaer F, Koka R, Singh Z, Hutnick E, Ruehle K, Lee ST, Kocoglu MH, Shanholtz C, Badros A, Hardy N, Yared J, Rapoport AP, Dahiya S. Rapid relapse of large B-cell lymphoma after CD19 directed CAR-T-cell therapy due to CD-19 antigen loss. Am J Hematol. 2019 10; 94(10):E273-E275.
-
Mirza MR, Bergmann TK, Mau-S?rensen M, Christensen RD, ?vall-Lundqvist E, Birrer MJ, J?rgensen M, Roed H, Malander S, Nielsen F, Lassen U, Br?sen K, Bj?rge L, M?enp?? J. A phase I study of the PARP inhibitor niraparib in combination with bevacizumab in platinum-sensitive epithelial ovarian cancer: NSGO AVANOVA1/ENGOT-OV24. Cancer Chemother Pharmacol. 2019 10; 84(4):791-798.
-
Zhang L, Yao Y, Zhang S, Liu Y, Guo H, Ahmed M, Bell T, Zhang H, Han G, Lorence E, Badillo M, Zhou S, Sun Y, Di Francesco ME, Feng N, Haun R, Lan R, Mackintosh SG, Mao X, Song X, Zhang J, Pham LV, Lorenzi PL, Marszalek J, Heffernan T, Draetta G, Jones P, Futreal A, Nomie K, Wang L, Wang M. Metabolic reprogramming toward oxidative phosphorylation identifies a therapeutic target for mantle cell lymphoma. Sci Transl Med. 2019 05 08; 11(491).
-
Chari A, Larson S, Holkova B, Cornell RF, Gasparetto C, Karanes C, Matous JV, Niesvizky R, Valent J, Lunning M, Usmani SZ, Anderson LD, Chang L, Lee Y, Pak Y, Salman Z, Graef T, Bilotti E, Chhabra S. Phase 1 trial of ibrutinib and carfilzomib combination therapy for relapsed or relapsed and refractory multiple myeloma. Leuk Lymphoma. 2018 11; 59(11):2588-2594.
-
Crowe MS, Wilson CD, Leishman E, Prather PL, Bradshaw HB, Banks ML, Kinsey SG. The monoacylglycerol lipase inhibitor KML29 with gabapentin synergistically produces analgesia in mice. Br J Pharmacol. 2017 Dec; 174(23):4523-4539.
-
Hankosky ER, Joolakanti SR, Nickell JR, Janganati V, Dwoskin LP, Crooks PA. Fluoroethoxy-1,4-diphenethylpiperidine and piperazine derivatives: Potent and selective inhibitors of [3H]dopamine uptake at the vesicular monoamine transporter-2. Bioorg Med Chem Lett. 2017 12 15; 27(24):5467-5472.
-
Srinivasan G, Sidhu GS, Williamson EA, Jaiswal AS, Najmunnisa N, Wilcoxen K, Jones D, George TJ, Hromas R. Synthetic lethality in malignant pleural mesothelioma with PARP1 inhibition. Cancer Chemother Pharmacol. 2017 Oct; 80(4):861-867.
-
Wells AM, Ridener E, Bourbonais CA, Kim W, Pantazopoulos H, Carroll FI, Kim KS, Cohen BM, Carlezon WA. Effects of Chronic Social Defeat Stress on Sleep and Circadian Rhythms Are Mitigated by Kappa-Opioid Receptor Antagonism. J Neurosci. 2017 08 09; 37(32):7656-7668.
-
Reyes HD, Miecznikowski J, Gonzalez-Bosquet J, Devor EJ, Zhang Y, Thiel KW, Samuelson MI, McDonald M, Stephan JM, Hanjani P, Guntupalli S, Tewari KS, Backes F, Ramirez N, Fleming GF, Filiaci V, Birrer MJ, Leslie KK. High stathmin expression is a marker for poor clinical outcome in endometrial cancer: An NRG oncology group/gynecologic oncology group study. Gynecol Oncol. 2017 08; 146(2):247-253.
-
Bae N, Viviano M, Su X, Lv J, Cheng D, Sagum C, Castellano S, Bai X, Johnson C, Khalil MI, Shen J, Chen K, Li H, Sbardella G, Bedford MT. Developing Spindlin1 small-molecule inhibitors by using protein microarrays. Nat Chem Biol. 2017 Jul; 13(7):750-756.
-
Bagherani N, Smoller BR. Efficacy of topical tofacitinib, a Janus kinase inhibitor, in the treatment of plaque psoriasis. Dermatol Ther. 2017 May; 30(3).
-
Owens SM, Pollard GT, Howard JL, Fennell TR, Snyder RW, Carroll FI. Pharmacodynamic Relationships between Duration of Action of JDTic-like Kappa-Opioid Receptor Antagonists and Their Brain and Plasma Pharmacokinetics in Rats. ACS Chem Neurosci. 2016 12 21; 7(12):1737-1745.
-
Tanda G, Mereu M, Hiranita T, Quarterman JC, Coggiano M, Katz JL. Lack of Specific Involvement of (+)-Naloxone and (+)-Naltrexone on the Reinforcing and Neurochemical Effects of Cocaine and Opioids. Neuropsychopharmacology. 2016 10; 41(11):2772-81.
-
Nickell JR, Culver JP, Janganati V, Zheng G, Dwoskin LP, Crooks PA. 1,4-Diphenalkylpiperidines: A new scaffold for the design of potent inhibitors of the vesicular monoamine transporter-2. Bioorg Med Chem Lett. 2016 07 01; 26(13):2997-3000.
-
Dai L, Trillo-Tinoco J, Cao Y, Bonstaff K, Doyle L, Del Valle L, Whitby D, Parsons C, Reiss K, Zabaleta J, Qin Z. Targeting HGF/c-MET induces cell cycle arrest, DNA damage, and apoptosis for primary effusion lymphoma. Blood. 2015 Dec 24; 126(26):2821-31.
-
Lee SH, Ledri M, T?th B, Marchionni I, Henstridge CM, Dudok B, Kenesei K, Barna L, Szab? SI, Renkecz T, Oberoi M, Watanabe M, Limoli CL, Horvai G, Soltesz I, Katona I. Multiple Forms of Endocannabinoid and Endovanilloid Signaling Regulate the Tonic Control of GABA Release. J Neurosci. 2015 Jul 08; 35(27):10039-57.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|